{"altmetric_id":20546522,"counts":{"readers":{"mendeley":23,"citeulike":0,"connotea":0},"total":{"posts_count":1},"policy":{"unique_users_count":1,"unique_users":["nice"],"posts_count":1}},"citation":{"abstract":"To assess the safety and effectiveness of olanzapine compared to typical antipsychotics in the treatment of first-episode schizophrenics in acute psychiatric inpatient wards.\nData were collected from a prospective, comparative, nonrandomized, open, observational study of 904 inpatients with schizophrenia. One hundred and fifty-eight patients fulfilled the criteria for first-episode schizophrenia, defined as (1) the International Classification of Diseases: Mental and Behavioral Disorders, 10th ed. (ICD-10) diagnosis of schizophrenia, (2) antipsychotic nai;ve, and (3) a course of illness of less than 5 years. Eighty-nine (56.3%) of these patients were assigned to the olanzapine treatment group (OLZ) and 69 (43.7%) to the control group that received treatment with conventional antipsychotics (CON). Safety was evaluated in terms of the spontaneous adverse events reported and a specific questionnaire for extrapyramidal symptoms (EPS). Clinical status was measured by means of the Brief Psychiatric Rating Scale (BPRS) and Clinical Global Impression of Severity (CGI-S). Clinical response was defined as the baseline-endpoint decrease in BPRS>40% plus an endpoint BPRS<18 or an endpoint CGI<\/=3.\nThe rate of clinical response to treatment in the OLZ was 76.7%, compared to 54.4% in the CON (chi(2)=8.48; P=.003). Olanzapine was significantly more effective than conventional antipsychotics in lowering the total BPRS score (P=.0003), as well as each of the following BPRS subscales: positive symptoms (P=.0019), negative symptoms (P<.0001), depression (P=.018), and agitation (P=.007), even after mean scores were adjusted for their baseline value and disease duration. Olanzapine also proved to be significantly superior to conventional antipsychotics in lowering mean CGI scores (P=.013). The frequency with which new EPS appeared, or previously existing ones worsened, was significantly greater in the CON than in the OLZ (55.1% vs. 13.5%; P<.001). Anticholinergics were needed more frequently in the CON than in the OLZ (58.0% vs. 6.7%; P<.0001).\nThe results of this observational, naturalistic study show that olanzapine is safe and effective in a nonselected sample of acute, first-episode schizophrenic inpatients.","altmetric_jid":"4f6fa5133cf058f6100033b5","authors":["Julio Bobes","Juan Gibert","Antonio Ciudad","Enrique Alvarez","Fernando Ca\u00f1as","Jos\u00e9-Luis Carrasco","Josep Gasc\u00f3n","Juan-Carlos G\u00f3mez","Miguel Guti\u00e9rrez"],"doi":"10.1016\/s0278-5846(03)00035-6","first_seen_on":"2017-05-26T09:50:12+00:00","issns":["02785846"],"issue":"3","journal":"Progress in Neuro-Psychopharmacology & Biological Psychiatry","last_mentioned_on":1375228800,"links":["http:\/\/dx.doi.org\/10.1016\/S0278-5846(03)00035-6"],"pmid":"12691783","pubdate":"2003-05-01T00:00:00+00:00","scopus_subjects":["Life Sciences","Pharmacology, Toxicology and Pharmaceutics","Neuroscience"],"subjects":["psychopharmacology","psychiatry"],"title":"Safety and effectiveness of olanzapine versus conventional antipsychotics in the acute treatment of first-episode schizophrenic inpatients","type":"article","volume":"27","mendeley_url":"http:\/\/www.mendeley.com\/research\/safety-effectiveness-olanzapine-versus-conventional-antipsychotics-acute-treatment-firstepisode-schi"},"altmetric_score":{"score":3,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":3},"context_for_score":{"all":{"total_number_of_other_articles":7772166,"mean":6.6362066801147,"rank":1902645,"this_scored_higher_than_pct":62,"this_scored_higher_than":4823221,"rank_type":"exact","sample_size":7772166,"percentile":62},"similar_age_3m":{"total_number_of_other_articles":99565,"mean":11.119509039412,"rank":29318,"this_scored_higher_than_pct":69,"this_scored_higher_than":69339,"rank_type":"exact","sample_size":99565,"percentile":69},"this_journal":{"total_number_of_other_articles":1081,"mean":4.3833037037037,"rank":267,"this_scored_higher_than_pct":58,"this_scored_higher_than":630,"rank_type":"exact","sample_size":1081,"percentile":58},"similar_age_this_journal_3m":{"total_number_of_other_articles":17,"mean":2.065625,"rank":4,"this_scored_higher_than_pct":76,"this_scored_higher_than":13,"rank_type":"exact","sample_size":17,"percentile":76}}},"demographics":{"users":{"mendeley":{"by_status":{"Unspecified":1,"Professor > Associate Professor":1,"Librarian":2,"Researcher":8,"Student  > Doctoral Student":2,"Student  > Ph. D. Student":4,"Student  > Postgraduate":1,"Other":1,"Student  > Master":1,"Student  > Bachelor":2},"by_discipline":{"Medicine and Dentistry":10,"Psychology":5,"Nursing and Health Professions":1,"Biochemistry, Genetics and Molecular Biology":1,"Unspecified":4,"Pharmacology, Toxicology and Pharmaceutical Science":2}}},"geo":{"mendeley":{"ES":1}}},"posts":{"policy":[{"title":"Psychosis and schizophrenia in children and young people: recognition and management: Appendix 13c - Clinical evidence study characteristics tables: Pharmacological interventions","url":"https:\/\/www.nice.org.uk\/guidance\/cg155\/evidence\/appendix-13c-clinical-evidence-study-characteristics-tables-pharmacological-interventions-6785647380","license":"public","citation_ids":[20544496,20544502,20544508,3280302,20544514,616642,20544519,20544525,5078587,20544538,20544542,20544544,5831020,20544553,20544564,20544568,20544582,20544586,20544593,240064,1419698,20544609,20544614,20544619,20544623,20544627,5496855,20544637,20544646,3191377,5078586,20544653,20544661,20544668,11949203,20544673,1187266,20544685,20544689,20544695,20544701,20544707,20544712,20544717,3148343,20544722,20544726,20544731,5752559,5585530,20544743,20544747,5824017,20544752,20544756,20544759,20544766,3628488,20544772,20544773,20544779,20544786,20544792,20544798,20544808,20544812,20544817,20544823,20544828,505823,20544839,20525090,20544842,20544849,20544857,20544861,20544870,20544878,2122245,20544888,20544894,461745,20544906,20544913,20544916,20544920,20544922,20544925,20544930,20544937,20544940,5751275,3726168,20544960,20544969,20544978,20544983,20544991,20544993,20544999,20545005,20545009,20545017,20545019,20545026,20545031,20545035,20545039,20545045,20545058,20545062,20545067,20545071,20545073,20545080,20545085,1140362,20545109,20545112,20545118,20545130,20545133,20193260,1554859,20545146,20545155,1609174,20545172,20545179,20545182,20545187,20545194,20545198,8232975,3386132,20545208,20545216,777644,20545229,20545234,20545241,20545249,20545254,20545261,20545264,20545271,20545275,20545279,20545292,20545297,20545300,902922,20545308,20545310,20545315,20545319,20545329,20545337,3347225,20545342,20545356,5579085,20545364,20545375,20545382,20545389,5784292,20403243,20545408,20545415,20545421,3449650,3563988,20545427,20545433,20545440,11786902,7605238,3098311,20545463,20545467,20545473,20545479,20545481,20545486,20545493,20545496,20545502,20545504,20545515,20545519,20545523,20545527,1079588,7413433,902937,20545542,445335,20545552,20545558,20545562,20545568,452744,422417,3200891,9943922,5756353,5784590,20545590,20545595,20545599,20545604,20545606,20545611,20545619,20545630,20545636,20545640,1908485,1449771,20545657,20545663,20545667,20545672,20545680,20545685,2432618,20545687,20545693,20545697,20545704,1625949,1112852,20545715,20545716,20545721,20545724,20545732,20545737,20545742,20545744,20545750,20545754,20545757,20545763,20545769,20545775,20545783,20545787,20545793,2414175,20545800,20545807,15776723,11769645,20545819,20545828,14486590,20545841,5503264,20545856,15009476,20545858,20545865,20545870,20545875,20545881,20545884,20545889,20545895,20545905,3138997,20545911,20545915,2414157,20545924,20545935,20545944,20545953,20545962,20545967,20545973,20545979,20545983,20545990,20545996,20546002,20546012,20546017,20546022,1037559,20546031,20546036,20546042,3338844,20546049,20546059,20546065,20546068,20546083,5810932,20546100,422334,3185823,20546112,555119,20546124,5636456,20546136,20546144,20546148,20546155,20546161,3619318,20546189,20546196,20546199,20546203,20546210,20546213,20546226,20546229,20546235,16703268,20546241,20546247,20546252,20546255,20546259,20546263,20546265,20546275,20546282,20546287,20546292,20546298,20546303,20546308,20546314,20546320,247428,20546326,5984226,1881771,20546344,20546347,20546356,13673728,20404292,20546375,20546380,20546383,854311,20546395,924680,2251025,20546411,20546422,20546428,20546434,519280,20546441,20546446,20546453,20546457,20546465,20546470,2916764,7410421,20546485,20546489,411951,7742358,20546501,295052,20546522,20546526,20546532,20546536,20546541,500990,20546548,20546551,20546555,20546558,13009755,20546560,20546565,10290227,20546577,20546582,20546593,20546598,20546607,20546612,20546618,20546620,15776773,20546632,20546637,20546649,3336942,20546654,20546672,20546681,20546688,20544327,20546695,1881773,20546708,20546713,465699,20546717,20546723,20546729,8188531,2432616,20546743,20546749,7435278,20546762,20402932,20546769,20546772,20546777,20546782,5786901,20546792,20546802,20546810,20546821,20546827,20546833,20546848,20546854,20546860,20546867,20546871,20546878,20546880,20546886,20546894,20546900,5078583,20546913,374749,20546924,11937692,20546932,20546939,20546950,20546955,20546964,20546970,20546976,434825,20546989,5441476,20547006,20547011,7407054,20547022,20547030,20547035,512243,20547039,15776752,20547046,20547051,20547059,20544135,1890536,20547074,20547079,20547084,20547089,3112848,389541,20547109,8256659,20547115,20547122,20547127,20547132,20547140,20547146,20547155,20547162,7859824,20547172,3221504,20547178,20547182,20547190,20547197,20547201,20547208,20547216,20547222,20547229,8060655,20547247,20547251,20547256,2432674,20547261,20547266,2116490,1224928,20547280,20547289,20547295,20547302,20547307,20547310,20547320,19701507,5726747,20547336,20547343,20543998,4975187,139894,2413953,20543814,20543825,20543888,20404273,20544163,20543789,20543809,1373533,224774,7605212,1213351,20547370,5755680,5707903,20544315,20547383,19492613],"posted_on":"2013-07-31T00:00:00+00:00","source":{"name":"National Institute for Health and Care Excellence","description":"The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.","geo":{"country":"GB"}},"page_url":"https:\/\/www.nice.org.uk\/guidance\/cg155\/evidence","collections":[],"author":{"image":"https:\/\/s3.amazonaws.com\/cache.altmetric.com\/policy\/thumbnails\/thumbnail-b6b980eb61d25db298fdd209325a1642d073c40cb25e7a48c28109e2d24ce5da.jpg"}}]}}